[18F]FAPI-74 serving as complementary diagnostic in Avacta Phase 1 trial

May 23, 2024 – SOFIE is pleased to partner with Avacta through Avacta’s use of [¹⁸F]FAPI-74 as a complementary diagnostic in their therapeutic studies targeting FAP. Avacta is evaluating the safety and tolerability of AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, in a Phase 1 trial.  A sub-study, utilizing [¹⁸F]FAPI-74 in PET scanning, has begun to better identify the expression of Fibroblast Activation Protein (FAP), shown to be overexpressed in cancer associated fibroblasts in the tumor microenvironment.

“SOFIE is excited to be advancing the clinical development of [¹⁸F]FAPI-74 PET for use in detection of FAP in areas of unmet need. We are leveraging our radiopharmaceutical manufacturing facilities in Totowa, NJ, and Gilroy, CA, to produce GMP grade [¹⁸F]FAPI-74 for clinical research. With four additional manufacturing sites planned for [¹⁸F]FAPI-74 production over the next 12 months, SOFIE looks forward to further supporting academic and industry partners’ access to FAPI for clinical research use,” stated Sherly Mosessian, Ph.D., SOFIE’s Chief Scientific Officer.

[¹⁸F]FAPI-74 PET is currently in clinical development and for investigational use only. SOFIE holds clinical development and commercialization rights for [¹⁸F]FAPI-74 in the US.

About SOFIE 
SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services and high value theranostic intellectual property, SOFIE is poised to deliver on the promise of radiopharmaceuticals. For more information visit our website, https://sofie.com/ or contact us by email at info@sofie.com

About FAPI
Fibroblast Activation Protein (FAP) is highly expressed in cancer associated fibroblasts (CAF) across several tumor entities. Developed by the team at the Heidelberg University, quinoline-based PET tracers that act as FAP inhibitors (FAPI) have shown encouraging results in pre-clinical and clinical studies.  SOFIE holds clinical development and commercialization rights for [¹⁸F]FAPI-74 in the US.

About [¹⁸F]FAPI-74

[¹⁸F]FAPI-74 is the lead Fluorine-18 radiolabeled PET tracer of FAPI family of compounds. It has demonstrated favorable dosimetry, avidity, safety and biodistribution profile amenable for detection of FAP-expressing cells in patients with various cancers. This radioligand for imaging is currently optimized for production within SOFIE and its clinical trial partners.